|
May 3
|
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
|
|
Apr 22
|
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
|
|
Apr 17
|
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
|
|
Apr 15
|
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
|
Apr 14
|
UroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week
|
|
Apr 3
|
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
|
|
Mar 17
|
UroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
|
|
Mar 15
|
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript
|
|
Mar 14
|
UroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challenges
|
|
Mar 14
|
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 14
|
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
|
|
Mar 4
|
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
|
|
Feb 26
|
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
|
|
Feb 23
|
Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?
|
|
Jan 11
|
UroGen Pharma to Participate in the B. Riley Healthcare Conference
|
|
Nov 27
|
Shareholders in UroGen Pharma (NASDAQ:URGN) are in the red if they invested five years ago
|
|
Nov 7
|
UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
|
|
Sep 8
|
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
May 22
|
With 58% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big guns
|